William F. Fadel

Regenstrief Institute — United States

Medicine · Health Sciences

27h-index3.9kcitations110works12.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(34), Vaccine Coverage and Hesitancy(30), COVID-19 Clinical Research Studies(20), Influenza Virus Research Studies(10), COVID-19 epidemiological studies(9)

Publications110 total

P-1435. Effectiveness of RSV Immunization among Infants in Their First RSV Season in the United States, 2023-2024 and 2024-2025 Seasons
Open Forum Infectious Diseases·2026Open Access
P-1517. Adult Respiratory Syncytial Virus Vaccination Receipt among Adults Testing Negative for RSV – VISION Network, October 1, 2024—March 31, 2025
Open Forum Infectious Diseases·2026Open Access
P-1501. Effectiveness of 2024–2025 seasonal influenza vaccines against influenza–associated hospitalizations among adults — VISION Network
Open Forum Infectious Diseases·2026Open Access
221. Effectiveness of RSV Vaccines in Older Adults in the United States, VISION Network, 2023-2025
Open Forum Infectious Diseases·2026Open Access
Effectiveness of 2023–2024 Coronavirus Disease 2019 (COVID-19) Vaccines in Pregnant Women
Obstetrics and Gynecology·2025
Comparing evidence-based telemental health treatments for caregivers of children with Prader Willi and Williams syndromes: feasibility, acceptability, and preliminary outcomes
Cognitive Behaviour Therapy·2025
Effectiveness of nirsevimab among infants in their first RSV season in the United States, October 2023–March 2024: a test-negative design analysis
The Lancet Regional Health - Americas·2025· 2 citedOpen Access
Effectiveness of 2023–2024 seasonal influenza vaccine against influenza-associated emergency department and urgent care encounters among pregnant and non-pregnant women of reproductive age
Vaccine·2025· 3 citedOpen Access
Correction: Optimizing a Personalized Health Approach for Virtually Treating High-Risk Caregivers of Children With Neurogenetic Conditions (Project WellCAST): Protocol for a Randomized Controlled Trial
JMIR Research Protocols·2025Open Access
Correction: Optimizing a Personalized Health Approach for Virtually Treating High-Risk Caregivers of Children With Neurogenetic Conditions (Project WellCAST): Protocol for a Randomized Controlled Trial (Preprint)
2025
Optimizing a Personalized Health Approach for Virtually Treating High-Risk Caregivers of Children With Neurogenetic Conditions (Project WellCAST): Protocol for a Randomized Controlled Trial
JMIR Research Protocols·2025Open Access
Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years — VISION and IVY Networks, September 2024–January 2025
MMWR Morbidity and Mortality Weekly Report·2025· 54 citedOpen Access
Methods to Adjust for Confounding in Test-Negative Design COVID-19 Effectiveness Studies: Simulation Study
JMIR Formative Research·2025· 2 citedOpen Access
Influenza Vaccine Effectiveness Against Hospitalizations and Emergency Department or Urgent Care Encounters for Children, Adolescents, and Adults During the 2023–2024 Season, United States
Clinical Infectious Diseases·2024· 13 citedOpen Access
Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis
The Lancet·2024· 78 cited
Tracking the burden, distribution, and impact of Post-COVID conditions in diverse populations for children, adolescents, and adults (Track PCC): passive and active surveillance protocols
BMC Public Health·2024· 5 citedOpen Access
Characterizing participants who respond to text, email, phone calls, or postcards in a SARS-CoV-2 prevalence study
BMC Public Health·2024· 1 citedOpen Access
Methods to Adjust for Confounding in Test-Negative Design COVID-19 Effectiveness Studies: Simulation Study (Preprint)
2024Open Access
Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions — VISION Network, September 2023–February 2024
MMWR Morbidity and Mortality Weekly Report·2024· 31 citedOpen Access
Risk of COVID‐19 Hospitalization and Protection Associated With mRNA Vaccination Among US Adults With Psychiatric Disorders
Influenza and Other Respiratory Viruses·2024· 2 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Brian E. Dixon(31), Shaun J. Grannis(27), Allison L. Naleway(27), Toan C. Ong(27), Stephanie A. Irving(27), Malini B. DeSilva(26), Kristin Dascomb(26), Karthik Natarajan(25), Bruce Fireman(25), Julie Arndorfer(25), Nicola P. Klein(24), Ousseny Zerbo(23), Michelle A. Barron(23), Manjusha Gaglani(23), Suchitra Rao(22), Kristin Goddard(22), Nimish R. Valvi(22), Sarah E. Reese(21), Monica Dickerson(21), Ruth Link‐Gelles(21)